afamitresgene autoleucel · TECELRA

Cell therapy

Approvedregulatory verdict

Evidence outlook

Approved: Synovial Sarcoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Synovial Sarcoma
Other / comorbidity
NCT04408898 · Adaptimmune
Run by former owner Adaptimmune Therapeutics
2020-07-02 – 2021-12 · Head and Neck Cancer
What this study did
Phase 1/2 (1)
Synovial Sarcoma
NCT05642455 · USWM CT, LLC
2023-09-01 – 2038-07-30 · Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.